New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
10:17 EDTJNJEarnings Preview: J&J investors will focus on catalysts, operating leverage
Johnson & Johnson (JNJ), a diversified, global healthcare conglomerate, is scheduled to report fourth quarter earnings before the open on Tuesday, January 21, with a conference call scheduled for 8:30 am ET. EXPECTATIONS: Analysts are looking for EPS of $1.20 on revenue of $17.95B, according to First Call. The consensus range for EPS is $1.19-$1.22 on revenue of $17.82B-$18.09B. LAST QUARTER: Johnson & Johnson reported Q3 adjusted EPS of $1.36 against estimates for $1.32 on revenue of $17.6B against estimates for $17.46B. At the time of its Q3 earnings release, J&J also raised its FY13 EPS view to $5.44-$5.49 from $5.40-$5.47. STREET RESEARCH: In a note to investors on January 7, RBC Capital said it expects the company's pharmaceutical franchise to continue to deliver above industry average revenue growth, and it predicts that the company will continue to have operating leverage, enabling its EPS to surpass consensus levels over the next several years. The firm raised its price target on J&J to $104 from $88. On January 10, Barclays downgraded shares of J&J to Equal Weight from Overweight. Barclays downgraded Johnson & Johnson citing limited catalysts and valuation.The firm kept its price target remains $99. PRICE ACTION: Since its last earnings report, shares of J&J are up approximately 5%. Over the last year, shares are up over 30%.
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
09:59 EDTJNJJohnson & Johnson to collaborate with Google to advance surgical robots
Subscribe for More Information
06:46 EDTJNJContact lens makers, discounters battling over price setting, NY Times says
Subscribe for More Information
March 25, 2015
07:29 EDTJNJLeerink to hold booth tours
Leerink Booth Tours at AAOS 2015 will be held in Las Vegas on March 25-26.
March 24, 2015
13:24 EDTJNJContact lens manufacturers accused of price-fixing, Bloomberg says
Subscribe for More Information
07:45 EDTJNJFDA Pediatric Advisory Committee holds a meeting
The Committee discusses pediatric-focused safety reviews, as mandated by the FDA Safety and Innovation Act (FDASIA) for Eli Lilly's Cymbalta, Pfizer's Quillivant XR and Revatio, Johnson & Johnson's Risperdal, GlaxoSmithKline's Advair, HFA Altabax Ointment and Fluarix Quadrivalent, Supernus Pharmaceuticals' Oxtellar XR, Teva Pharmaceutical's Qnasl and Roche's Invirase. The Committee will also discuss the safety ongoing propriety of the humanitarian device exemption for the Medtronic Activa Dystonia Therapy and for the Liposorber LA-15 System in a meeting being held in Silver Spring, Maryland on March 24 at 8 am. Webcast Link
March 23, 2015
09:03 EDTJNJLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
March 17, 2015
05:35 EDTJNJJohnson & Johnson to invest $10M in UK government fund to fight dementia
Subscribe for More Information
March 16, 2015
15:04 EDTJNJPharmacyclics says committee recommends unblinding after primary endpoint met
Subscribe for More Information
March 13, 2015
14:34 EDTJNJU.S. appeals court revives lawsuit over J&J's Benecol assertions
Subscribe for More Information
07:23 EDTJNJJohnson & Johnson has a conference call hosted by JPMorgan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use